Skip to main content

Table 1 Demographics, comorbidities and clinical features upon admission of patients with necrotizing skin and soft tissue infections before (n = 60), during (n = 35) and after (n = 129) the implementation of a dedicated multimodal and multidisciplinary bundle

From: Impact of a multidisciplinary care bundle for necrotizing skin and soft tissue infections: a retrospective cohort study

  Available data All patients
n = 224
Pre-implementation period (2006–2011)
n = 60
Implementation period (2012–2013)
n = 35
Post-implementation period (2014–2017)
n = 129
p a
Demographics
 Age, years, median (IQR) 224 64 (53–74) 66 [55–76] 68 [60–75] 61 [53–72] 0.193
 Male gender, n (%) 127 (56.7) 34 (56.7) 17 (48.6) 76 (58.9) 0.894
Comorbidities, n (%)
 Diabetes mellitus 224 83 (37.1) 18 (30.0) 12 (34.3) 53 (41.1) 0.192
 Immunodeficiency 58 (25.9) 13 (21.7) 14 (40.0) 31 (24.0) 0.863
  HIV infection 2 (0.9) 1 (1.7) 1 (2.9) 0 (0.0) 0.694
  Cancer 21 (9.4) 5 (8.3) 7 (20.0) 9 (7.0) 0.974
  Corticosteroids 36 (16.1) 6 (10.0) 9 (25.7) 21 (16.3) 0.355
 Obliterating arteritis of the lower limbs 24 (10.7) 6 (10.0) 4 (11.4) 14 (10.9) > 0.99
 Liver cirrhosis 9 (4.0) 1 (1.7) 2 (5.7) 6 (4.7) 0.550
 Chronic kidney disease 25 (11.2) 7 (11.7) 5 (14.3) 13 (10.1) 0.939
 Chronic alcohol consumption 27 (12.1) 7 (11.7) 5 (14.3) 15 (11.6) > 0.99
 Obesity 57 (25.4) 16 (26.7) 10 (28.6) 31 (24.0) 0.834
Prior to admission
 Time from first symptom, days, median (IQR) 214 5 [2–10] 6 [2–12] 4 [1–15] 5 [3–9] 0.848
 Antibiotic treatment, n (%) 221 137 (61.2) 33 (55.9) 20 (58.8) 84 (65.6) 0.267
 NSAID use, n (%) 222 46 (20.5) 9 (15.0) 4 (11.8) 33 (26.0) 0.143
 Transferred from another center, n (%) 223 116 (51.8) 31 (51.7) 16 (47.1) 69 (53.5) 0.939
Presentation upon admission
 Nosocomial infection, n (%) 222 45 (20.1) 20 (33.3) 8 (23.5) 17 (13.4) 0.002
 Infection site, n (%) 223  
  Inferior limbs 173 (77.2) 40 (66.7) 30 (85.7) 103 (80.5) 0.060
  Superior limbs 19 (8.5) 8 (13.3) 1 (2.9) 10 (7.8) 0.351
  Abdomino-perineal infection 38 (17.0) 13 (21.7) 4 (11.4) 21 (16.4) 0.503
  Cervico-facial infection 2 (0.9) 0 (0.0) 0 (0.0) 2 (1.6) 0.833
  Other 1 (0.4) 0 (0.0) 0 (0.0) 1 (0.8) 1
 Multifocal infection, n (%) 223 23 (10.3) 5 (8.3) 4 (11.4) 14 (10.9) 0.770
 Shock, n (%) 220 91 (40.6) 30 (50.8) 12 (34.3) 49 (38.9) 0.170
  1. HIV human immunodeficiency virus, NSAID non-steroidal anti-inflammatory drug
  2. ap values for univariate comparison of the pre- and post-implementation periods; Chi-squared test or Fisher’s exact test were used for categorical data according to sample size, Mann–Whitney’s test were used for continuous variables due to non-parametrical distribution